肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2014 第5届亚太原发性肝癌专家会议共识报告：手术治疗中晚期肝细胞癌

2014-07-01 亚太肝细胞癌专家组 Liver Cancer. 2016 Oct;5(4):245-256.

抗癌

该共识报告来自第5届亚太原发性肝癌专家会议，主要目的是分享中晚期肝癌肝切除术的专家观点和经验并为改期患者手术治疗提供相关证据建议。

中文标题：

2014 第5届亚太原发性肝癌专家会议共识报告：手术治疗中晚期肝细胞癌

英文标题：

Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

发布机构：

亚太肝细胞癌专家组

发布日期：

2014-07-01

简要介绍：

巴塞罗那肝癌分期 (BCLC)和治疗策略不建议手术治疗BCLC分期B和C期肝细胞癌。然而，许多亚太医疗机构仍然倾向对改期患者进行手术治疗。该共识报告来自第5届亚太原发性肝癌专家会议，主要目的是分享中晚期肝癌肝切除术的专家观点和经验并为改期患者手术治疗提供相关证据建议。 拓展指南：与肝癌相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2014 第5届亚太原发性肝癌专家会议共识报告：手术治疗中晚期肝细胞癌)] GetToolGuiderByIdResponse(projectId=1, id=0acad1c001335003, title=2014 第5届亚太原发性肝癌专家会议共识报告：手术治疗中晚期肝细胞癌, enTitle=Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)., guiderFrom=Liver Cancer. 2016 Oct;5(4):245-256., authorId=null, author=, summary=该共识报告来自第5届亚太原发性肝癌专家会议，主要目的是分享中晚期肝癌肝切除术的专家观点和经验并为改期患者手术治疗提供相关证据建议。, cover=, journalId=null, articlesId=null, associationId=1329, associationName=亚太肝细胞癌专家组, associationIntro=, copyright=0, guiderPublishedTime=Tue Jul 01 00:00:00 CST 2014, originalUrl=, linkOutUrl=, content=巴塞罗那肝癌分期 (BCLC)和治疗策略不建议手术治疗BCLC分期B和C期肝细胞癌。然而，许多亚太医疗机构仍然倾向对改期患者进行手术治疗。该共识报告来自第5届亚太原发性肝癌专家会议，主要目的是分享中晚期肝癌肝切除术的专家观点和经验并为改期患者手术治疗提供相关证据建议。 拓展指南：<strong>与<font color="red">肝癌</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=661011c0012916b7" title="2016 注射用洛铂在原发性肝癌TACE 治疗中的专家共识" target="_blank">2016 注射用洛铂在原发性肝癌TACE 治疗中的专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=b07701c00119ea51" title="肝细胞肝癌合并门静脉癌栓多学科团队综合治疗广东专家共识（2015版）" target="_blank">肝细胞肝癌合并门静脉癌栓多学科团队综合治疗广东专家共识（2015版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6c4f21c0011e3753" title="北方肝癌治疗专家委员会肝细胞癌诊疗共识(草案)2014" target="_blank">北方肝癌治疗专家委员会肝细胞癌诊疗共识(草案)2014</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=c37f91c00115037f" title="原发性肝癌规范化病理诊断指南（2015版）" target="_blank">原发性肝癌规范化病理诊断指南（2015版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6417f1c001095571" title="肝癌多学科联合治疗策略与方法——广东专家共识（1）" target="_blank">肝癌多学科联合治疗策略与方法——广东专家共识（1）</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E8%82%9D%E7%99%8C" target="_blank">有关肝癌更多指南</a></ul>, tagList=[TagDto(tagId=715, tagName=抗癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4491, appHits=94, showAppHits=0, pcHits=3436, showPcHits=1375, likes=140, shares=1, comments=3, approvalStatus=1, publishedTime=Fri Nov 25 14:54:25 CST 2016, publishedTimeString=2014-07-01, pcVisible=1, appVisible=1, editorId=5295955, editor=yingzheng.gu, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=yingzheng.gu, createdTime=Fri Nov 25 14:54:25 CST 2016, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 11:30:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2014 第5届亚太原发性肝癌专家会议共识报告：手术治疗中晚期肝细胞癌)])
2014 第5届亚太原发性肝癌专家会议共识报告：手术治疗中晚期肝细胞癌
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=158709, encodeId=cb48158e096b, content=指南指的好，工作脾气小, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 28 15:42:56 CST 2016, time=2016-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158406, encodeId=2e2a1584069d, content=文章不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Nov 27 07:25:43 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158221, encodeId=6ed515822152, content=阅读了谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Nov 26 08:08:58 CST 2016, time=2016-11-26, status=1, ipAttribution=)]
    2016-11-28 李东泽

    指南指的好，工作脾气小

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=158709, encodeId=cb48158e096b, content=指南指的好，工作脾气小, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 28 15:42:56 CST 2016, time=2016-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158406, encodeId=2e2a1584069d, content=文章不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Nov 27 07:25:43 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158221, encodeId=6ed515822152, content=阅读了谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Nov 26 08:08:58 CST 2016, time=2016-11-26, status=1, ipAttribution=)]
    2016-11-27 1e10c84am36(暂无匿称)

    文章不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=158709, encodeId=cb48158e096b, content=指南指的好，工作脾气小, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Nov 28 15:42:56 CST 2016, time=2016-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158406, encodeId=2e2a1584069d, content=文章不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Nov 27 07:25:43 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158221, encodeId=6ed515822152, content=阅读了谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Nov 26 08:08:58 CST 2016, time=2016-11-26, status=1, ipAttribution=)]
    2016-11-26 刘煜

    阅读了谢谢分享

    0